{"name":"Reinhard Dummer","slug":"reinhard-dummer","ticker":"","exchange":"","domain":"","description":"Reinhard Dummer is a research-focused biopharmaceutical company primarily involved in the development of oncology treatments. The company's lead product, Cemiplimab Injection [Libtayo], is currently in Phase 2 clinical trials, highlighting its commitment to advancing innovative therapies for cancer patients.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBtMUhIRjNPcTUxMnZlRmw2U210NG8tLXFCSVVCdWx6NGlyeFYwN0hZV0pqbjFCWFRRekxNY1Y5WXZMNnYxRVJscmtOSUgwc3hkMFNwanQ4blg5cXEtbmRJV2FLT1JPdHBw?oc=5","date":"2024-09-09","type":"trial","source":"Wiley Online Library","summary":"Gender differences in melanoma awareness, diagnosis and treatment: Patient-reported data from a multicentre survey in Switzerland - Wiley Online Library","headline":"Gender differences in melanoma awareness, diagnosis and treatment: Patient-reported data from a multicentre survey in Sw","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBWMGVPQnZaLTk2ODBUWUdJcU1ZWTVpWXV3X3VuVUVsWXBNbm9wem4zcUg2TE9KQnotVEhZc2RUbkxWeWRYczhhQzZCMHNxcnhSd2U0ZUFmZE12WmNIeE0tUw?oc=5","date":"2020-09-02","type":"pipeline","source":"NEJM","summary":"Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma - NEJM","headline":"Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}